Bloomberg recently highlighted RegASK insights on the growing challenges pharmaceutical companies face due to new U.S. tariffs. The article highlights how drug manufacturers are responding by increasing stockpiles and exploring alternative supply chain strategies.
Caroline Shleifer, CEO of RegASK, shared how companies are adjusting to the uncertainty:
“Most companies that have drugs with sufficient shelf life want to have at least three to six months of stock in the US while they reassess the possible impact and try to figure out potential workarounds on the tariffs.”
With pharmaceutical firms ramping up airfreight shipments and exploring regulatory solutions, RegASK provides AI-powered intelligence to help businesses navigate evolving trade policies.
Read the full Bloomberg article aquí
